HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leukemia derived from intermediately differentiated lymphocytic lymphoma.

Abstract
The availability of monoclonal antibodies has facilitated the immunophenotypic characterization of malignant lymphocytes from patients with lymphoma and leukemia. The chronic lymphocytic leukemias are diseases of both clinical and morphological diversity and the application of monoclonal antibodies can prove helpful in their classification. Enzyme cytochemistry, surface markers, mouse rosetting, and electron microscopy were used to determine the phenotype of cells from an atypical case of B-CLL. The use of monoclonals Leu-1, CALLA and BA-2 on bone marrow and peripheral blood provided the opportunity to diagnose this patient's disease as intermediately differentiated lymphoma. Leu-1 was found to be a useful alternative to mouse rosetting, a technique not easily performed in a routine setting. Ultrastructural studies helped to prove the prolymphocytic component of this patient's disease. It was concluded that phenotypic characterization of lymphoid cells using monoclonal antibodies directed against membrane antigens facilitated the assessment of this patient's disease.
AuthorsJ M Elias, F Fromowitz, M Golightly, B Lane, S Sabet
JournalPathology, research and practice (Pathol Res Pract) Vol. 183 Issue 1 Pg. 54-64 (Feb 1988) ISSN: 0344-0338 [Print] Germany
PMID3283712 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antigens, Surface
Topics
  • Antigens, Surface (analysis)
  • B-Lymphocytes
  • Cell Differentiation
  • Cell Transformation, Neoplastic
  • Histocytochemistry
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (complications, pathology)
  • Leukemia, Lymphoid (enzymology, etiology, pathology)
  • Lymphoid Tissue (pathology, ultrastructure)
  • Male
  • Middle Aged
  • Phenotype

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: